Skip to Content
Merck
  • Resolution of sertraline with (R)-mandelic acid: chiral discrimination mechanism study.

Resolution of sertraline with (R)-mandelic acid: chiral discrimination mechanism study.

Chirality (2011-12-17)
Quan He, Sohrab Rohani, Jesse Zhu, Hassan Gomaa
ABSTRACT

The chiral discrimination mechanism in the resolution of sertraline with mandelic acid was investigated by examining the weak intermolecular interactions (such as hydrogen bond, CH/π, and van der Waals interactions) and molecular packing difference in crystal structures of the resulting diastereomeric salts. A new one-dimensional chain-like hydrogen-bonding network and unique supramolecular packing mode are disclosed. The investigation demonstrated that stable hydrogen-bonding pattern, herringbone-like arrangement of aromatic rings, and planar boundary surface in the hydrophobic region are the three most important structural characteristics expected in less soluble diastereomeric salts. The existence and magnitude of hydrogen bond, CH/π interaction, and van der Waals interaction related to three characteristic structures, determine the stability of diastereomeric salt. The hydrogen bond is not necessarily the dominant factor while the synergy and optimization of all weak intermolecular interactions attribute to the chiral recognition.

MATERIALS
Product Number
Brand
Product Description

Sertraline impurity E, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
(R)-(−)-Mandelic acid, ReagentPlus®, ≥99%
Sigma-Aldrich
(R)-(−)-Mandelic acid, 98%
Sigma-Aldrich
Mandelic acid, 99%
Sigma-Aldrich
(R)-(−)-Mandelic acid, ChiPros®, produced by BASF, 99%
Supelco
DL-Mandelic acid, analytical standard